Annexon, Inc. (ANNX) earnings date
Mar 15, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 18 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | before open | 43 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Mon, Mar 30, 2026 | after close | 89 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | after close | 41 | 8-K |
| Q2 FY2025 | Thu, Aug 14, 2025 | after close | 45 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | after close | 42 | 8-K |
| Q4 FY2024 | Mon, Mar 3, 2025 | after close | 62 | 8-K |
What they guided beta
| Q3 FY2026 | "Next Milestone: EMA review of MAA underway; BLA submission with U.S./European data from FORWARD expected fourth quarter of 2026." exhibit |
| Q3 FY2026 | "ARCHER II completion, including Month 24 analyses, is expected in the third quarter of 2027." exhibit |
| Q3 FY2026 | "Next Milestones: ARCHER II Phase 3 Month 15 single study primary endpoint assessment expected in the fourth quarter of 2026; ARCHER II completion, including Month 24 analyses, expected in the third quarter of 2027." exhibit |
| Q3 FY2026 | "Cash and operating runway: Cash, cash equivalents and short-term investments were $213.4 million as of September 30, 2026, which are expected to fund operations and anticipated milestones into 2028." exhibit |
| Q2 FY2026 | "Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026 Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study; Month 15 Primary Endpoint on Track for Q4 2026 POC Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in F" exhibit |
| Q2 FY2026 | "“With our leadership capabilities and financial position strengthened, we are entering an exciting period of execution, with multiple important clinical and regulatory milestones expected over the next 6 to 12 months and a significant opportunity to create value for patients and stakeholders.” 2026 Strategic Priorities and Key Milestones Tanruprubart: Potential to be the first targeted, fast-acting therapy for GBS, an indiscriminate life-threatening neuromuscular emergency affecting 150,000 people annually worldwide and driving an estimated $20+ billion annual healthcare burden in the U.S." exhibit |
| Q2 FY2026 | "Next Milestone: Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026." exhibit |
| Q2 FY2026 | "Next Milestones: Month 15 primary endpoint on track for the fourth quarter of 2026, with final trial completion, including the Month 24 primary endpoint expected in the third quarter of 2027." exhibit |
| Q2 FY2026 | "Annexon’s current cash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ANNX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ANNX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ANNX/"><img src="https://veritasdata.dev/embed/ANNX.svg" alt="ANNX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ANNX/)
Script
<script async src="https://veritasdata.dev/embed/ANNX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ANNX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.